| Literature DB >> 26558275 |
Henning Heßler1, Hanna Zimmermann1, Timm Oberwahrenbrock1, Ella Maria Kadas1, Janine Mikolajczak1, Alexander U Brandt1, Andreas Kauert2, Friedemann Paul3, Stephan J Schreiber4.
Abstract
INTRODUCTION: Carotid artery disease (CAD) comprising high-grade internal carotid artery stenosis (CAS) or carotid artery occlusion (CAO) may lead to ipsilateral impaired cerebral blood flow and reduced retinal blood supply.Entities:
Mesh:
Year: 2015 PMID: 26558275 PMCID: PMC4628976 DOI: 10.1155/2015/604028
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1(a)–(c) Transorbital ultrasound measurement of flow velocities in the central retinal artery (CRA) in a patient with carotid artery occlusion (CAO) and retrograde OA blood flow. (a) Transorbital B-mode scan of the optic nerve and color-mode imaging of the CRA. (b) Flow velocities ipsilateral to the CAO. Besides the reduced absolute flow velocity, there is a markedly delayed systolic flow rise. (c) Flow velocity of the no-CAD side. Note the normal steep systolic flow rise. (d) Exemplary peripapillary OCT ring scan with sectors: temporal (T), superior (S), inferior (I), and nasal (N). (e) Exemplary presentation of an OCT macular volume scan with segmentation of the retinal nerve fiber layer (RNFL) and combined ganglion cell and inner plexiform layer (GCIPL).
Demographic details of the total cohort and stenosis subgroups. SD: standard deviation; min: minimal; max: maximal; CAD: carotid artery disease comprising carotid artery stenosis (CAS) and carotid artery occlusion (CAO); HLP: hyperlipoproteinemia; PAD: peripheral artery disease; TIA: transient ischemic attack; Group 1: CAS 50–79%; Group 2: CAS ≥ 80% or CAO with nonretrograde OA; Group 3: CAS ≥ 80% or CAO with retrograde OA.
| Total cohort | Stenosis subgroups | |||
|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | ||
| Patients | 27 | 8 | 7 | 12 |
| Sex | ||||
| Male | 17 (63%) | 7 (87.5%) | 2 (28.6%) | 8 (66.7%) |
| Female | 10 (37%) | 1 (12.5%) | 5 (71.4%) | 4 (33.3%) |
| Age (years) | ||||
| Mean ± SD | 61 ± 10 | 66 ± 4 | 62 ± 7 | 58 ± 12 |
| (min–max) | (35–76) | (61–72) | (50–71) | (35–76) |
| Disease duration CAD (months) | ||||
| Mean ± SD | 46 ± 50 | 21 ± 20 | 74 ± 55 | 46 ± 56 |
| (min–max) | (1–177) | (2–58) | (6–177) | (1–169) |
| Unilateral CAD | ||||
| 50–79% | 8 (29.6%) | 8 (100%) | 0 | 0 |
| 80–99% | 9 (33.3%) | 0 | 5 (71.4%) | 4 (33.3%) |
| Occlusion | 10 (37.0%) | 0 | 2 (28.6%) | 8 (66.7%) |
| Comorbidity | ||||
| Art. hypertension | 18 (66.7%) | 7 (87.5%) | 5 (71.4%) | 6 (50.0%) |
| HLP | 14 (51.9%) | 4 (50.0%) | 3 (42.9%) | 7 (58.3%) |
| Coronary artery disease | 8 (29.6%) | 4 (50.0%) | 1 (14.3%) | 3 (25.0%) |
| Diabetes mellitus | 4 (14.8%) | 2 (25.0%) | 1 (14.3%) | 1 (8.3%) |
| PAD | 3 (11.1%) | 1 (12.5%) | 1 (14.3%) | 1 (8.3%) |
Side-to-side differences (no-CAD versus CAS/CAO) of sonographic results in the CRA peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) and the optic nerve thicknesses optic nerve sheath diameter (ONSD) and optic nerve diameter (OND). Significant findings in PSV for the total cohort (p = 0.007) and Group 3 (p = 0.005) and ONSD (p = 0.028) and OND (0.027) in Group 2. CAD: carotid artery disease; CAS: carotid stenosis; CAO: carotid artery occlusion, Group 1: CAS 50–79%; Group 2: CAS ≥ 80% or CAO with nonretrograde OA; Group 3: CAS ≥ 80% or CAO with retrograde OA; SD: standard deviation; CoV: coefficient of variation. Paired sample Wilcoxon sign rank test was used for intereye comparisons (no-CAD versus CAS/CAO).
| Total cohort | Stenosis groups | ||||
|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | |||
| PSV |
| 24 | 6 | 6 | 12 |
| No-CAD | 0.125 ± 0.030 (0.238) | 0.120 ± 0.029 (0.239) | 0.119 ± 0.018 (0.152) | 0.130 ± 0.035 (0.272) | |
| CAS/CAO | 0.105 ± 0.025 (0.241) | 0.116 ± 0.023 (0.195) | 0.109 ± 0.021 (0.191) | 0.098 ± 0.028 (0.287) | |
|
|
| 0.893 | 0.463 |
| |
|
| |||||
| EDV |
| 24 | 6 | 6 | 12 |
| No-CAD | 0.037 ± 0.017 (0.460) | 0.034 ± 0.010 (0.308) | 0.032 ± 0.009 (0.273) | 0.040 ± 0.022 (0.544) | |
| CAS/CAO | 0.034 ± 0.014 (0.413) | 0.038 ± 0.016 (0.434) | 0.033 ± 0.008 (0.225) | 0.032 ± 0.016 (0.491) | |
|
| 0.493 | 0.463 | 0.917 | 0.147 | |
|
| |||||
| RI |
| 24 | 6 | 6 | 12 |
| No-CAD | 0.72 ± 0.08 (0.109) | 0.71 ± 0.06 (0.089) | 0.73 ± 0.04 (0.054) | 0.71 ± 0.10 (0.141) | |
| CAS/CAO | 0.69 ± 0.10 (0.145) | 0.68 ± 0.12 (0.176) | 0.70 ± 0.04 (0.052) | 0.68 ± 0.12 (0.170) | |
|
| 0.063 | 0.416 | 0.093 | 0.307 | |
|
| |||||
| ONSD |
| 27 | 8 | 7 | 12 |
| No-CAD | 0.477 ± 0.060 (0.125) | 0.473 ± 0.066 (0.140) | 0.468 ± 0.045 (0.095) | 0.484 ± 0.066 (0.113) | |
| CAS/CAO | 0.480 ± 0.066 (0.138) | 0.465 ± 0.096 (0.207) | 0.500 ± 0.047 (0.093) | 0.478 ± 0.054 (0.113) | |
|
| 0.471 | 1.000 |
| 0.937 | |
|
| |||||
| OND |
| 27 | 8 | 7 | 12 |
| No-CAD | 0.291 ± 0.045 (0.156) | 0.287 ± 0.059 (0.207) | 0.270 ± 0.037 (0.137) | 0.306 ± 0.037 (0.119) | |
| CAS/CAO | 0.300 ± 0.042 (0.141) | 0.295 ± 0.059 (0.199) | 0.304 ± 0.027 (0.089) | 0.300 ± 0.040 (0.134) | |
|
| 0.275 | 0.726 |
| 0.929 | |
Figure 2Results of peak systolic velocity (PSV) in the central retinal artery (CRA). (a) shows the individual measurements in stenosis subgroups. (b) shows PSV differences (PSV intereye difference = PSV CAS/CAO side − PSV no-CAD side) of stenosis subgroups. CAD: carotid artery disease; CAS: carotid artery stenosis; CAO: carotid artery occlusion, Group 1: CAS 50–79%; Group 2: CAS ≥ 80%/CAO with nonretrograde OA; Group 3: CAS ≥ 80%/CAO with retrograde OA.
Side-to-side differences (no-CAD versus CAS/CAO) of OCT and functional measurements with no significant findings. RNFL: peripapillary retinal nerve fiber layer; G: global; S: superior; N: nasal; I: inferior; T: temporal; TMV: total macula volume; GCIPL: ganglion cell/inner plexiform layer; ONHV: optic nerve head volume; HCVA: high-contrast visual acuity; LCVA: low-contrast visual acuity (photopic = 85 cd/m2, mesopic = 3 cd/m2); CAD: carotid artery disease; CAS: carotid artery stenosis; CAO: carotid artery occlusion, ± standard deviation. Paired sample Wilcoxon sign rank test was used for intereye comparisons (no-CAD versus CAS/CAO).
|
| No-CAD | CAS/CAO |
| |
|---|---|---|---|---|
| RNFL-G thickness ( | 15 | 101 ± 8 | 99 ± 9 | 0.363 |
| RNFL-S thickness ( | 15 | 126 ± 11 | 126 ± 14 | 0.363 |
| RNFL-N thickness ( | 15 | 76 ± 10 | 73 ± 14 | 0.100 |
| RNFL-I thickness ( | 15 | 128 ± 15 | 129 ± 21 | 0.977 |
| RNFL-T thickness ( | 15 | 70 ± 11 | 69 ± 11 | 0.637 |
| TMV (mm3) | 15 | 8.62 ± 0.41 | 8.68 ± 0.41 | 0.083 |
| GCIPL volume (mm3) | 15 | 1.96 ± 0.12 | 1.97 ± 0.13 | 0.344 |
| ONHV (mm3) | 13 | 1.253 ± 0.158 | 1.275 ± 0.288 | 0.972 |
| HCVA (decimal) | 15 | 1.11 ± 0.45 | 1.01 ± 0.31 | 0.206 |
| LCVA photopic (AUC) | 14 | 1.925 ± 0.198 | 1.997 ± 0.097 | 0.158 |
| LCVA mesopic (AUC) | 12 | 1.676 ± 0.333 | 1.698 ± 0.186 | 0.937 |
Figure 3Scatterplot describing the significant correlation (p = 0.005) between the disease duration of the CAS/CAO and the intereye difference of the total macular volume (TMV). Patients with initial CAS/CAO diagnosis in the last 15 months show thickening of the TMV. TMV intereye difference = TMV CAS/CAO side − TMV no-CAD side. CAD: carotid artery disease; CAS: carotid artery stenosis; CAO: carotid artery occlusion. Spearman-Rho test was used.